Mas texto en la ventana.
The ten biggest funds at Biospain 2016 manage assets of over 5 billion euros
Among the confirmed investment funds are Forbion, Johnson & Johnson Innovation, Novartis Venture Fund, Ysios Capital Partners, Caixa Capital Risc and Cross Road Biotech
Bilbao, 28 September 2016. The eight edition of Biospain 2016, the International Biotechnology Meeting (http://www.biospain2016.org), organised by the Spanish Bioindustry Association (ASEBIO) and SPRI (Basque Business Development Agency), part of the Basque Government, the event takes place between the 28 and 30 of September in Bilbao, coinciding with the European Biotech Week (http://www.biotechweek.org/), with the presence of 45 national and international investment funds. The ten biggest of these manage capital totalling 5.3 billion euros in the health sciences, included in this group are Forbion, Johnson & Johnson Innovation, Novartis Venture Fund, Ysios Capital Partners, Caixa Capital Risc and Cross Road Biotech. Also present will be Edmond de Rothschild Investment Partners, which manages 150 billion euros across ten business areas. The Biospain Investment Forum, with the collaboration of the Spanish Venture Capital & Private Equity Association, is aiming to attract both national and international investors.
Ion Arocena, General Manager of ASEBIO, explained during the press conference for the opening ceremony in Bilbao that “as shown by the latest operations in the sector, as well as the presence of international investors, Spanish biotechnology is increasingly attractive to international investors and companies. This edition there are a total of 45 investors, for whom there is a full conference programme and business project presentations by 23 Spanish companies.”
Greater US presence
Biospain, which is being held in the Bilbao Exhibition Centre (BEC), Barakaldo, will have a greater presence of US companies with the United States as guest country for this eight edition. There will be entities from the states of Maryland, Massachusetts, North Carolina, Pennsylvania, Texas, Virginia and Puerto Rico. “We are expecting 700 companies and 1,500 participants, that makes us the fifth biggest biotechnology event in the world in terms of business meetings,” stated Arocena.
At this time, 26 countries have confirmed their presence at Biospain 2016, meaning international attendance now makes up 33% of the total. According to declarations made by Jordi Martí, President of ASEBIO, during the opening ceremony, “the US plays host to the largest single number of subsidiaries of ASEBIO members, with 21 already stablished in the US market. At recent international fairs, we have found a growing interest by international investors and company clusters in coming here to find out about projects in Spain as well as bringing companies from abroad, particularly the United States, Europe and Latin America.” Also present at the opening ceremony were Keith Silver, the Deputy Senior Commercial Officer at the US Embassy, Francisco Javier Garzón, Chief Executive Officer of ICEX; Elena Andradas, Director General for Public Health, Quality and innovation at the Ministry of Health, Social Services and Equality; and Arantxa Tapia, the Minister for Economic Development and Competitiveness of the Basque Government.
There has also been an increase of participation in terms of autonomous community pavilions, with Galicia, the Basque Country, Catalonia, Valencia and the Balearic Islands all having one this year. There is 40% more floor space for the commercial fair than during the previous edition. The partnering space will be similar to that used for the previous event, although the total number of partnering meetings is expected to surpass the 3,300 that took place at Santiago de Compostela during Biospain 2014.
Highlighting the international competitiveness of Spanish biotechnology companies and the quality of their scientific output, Europabio recently announced that three of the seven finalists for the Biotech SME Awards, a prize for the most innovative companies in Europe, were Spanish companies; Oryzon, TiGenix and Plant Response.
“Hosting an event like Biospain on home soil allows us to present and position our activities in this industry on the international stage, providing for the commercial, investment, academic and information needs of the sector,” explained Alexander Arriola, General Director of SPRI, the Basque Business Development Agency, Department of Economic Development and Competitiveness of the Basque Government. He went on to underline that this is the second time the event takes place in the Basque Country: “This reaffirms Euskadi as a leader in knowledge and technology intensive initiatives, as well as recognising the commitment of the Basque Government to life sciences, a commitment which started in the year 2000 with a determined push to adapt the Basque economy to an increasingly changing and competitive world”.
Jordi Martí also drew attention to the fact that “biotechnology has tools to respond to the health challenges set out during the last G7 summit in Japan, which were focused on expanding universal healthcare, the challenges of ageing, responding to public health emergencies, combating antimicrobial resistance, supporting R&D and, in short, establishing sustainable healthcare systems.”
Key subjects for discussion will include CRISPR technology, a gene editing technique with multiple biotechnology applications that was first pioneered by Francisco Mojica, a Microbiology Professor at the University of Alicante who will participate in the event as a speaker; and Big Data, a new challenge for the biotechnology industry and an opportunity to use information effectively and thereby extract value from it. Other areas to be covered during the event include new diagnostics methods; vaccines; Alzheimer's; food and health; public policies for open innovation; nanobiotechnology; new oncology therapies, and bioeconomy.
New for this year is a Patient Forum on rare diseases, developments in multiple sclerosis and the role of patient associations. On Friday 30 the Pharma Biotech Forum for the Pharma industry will also take place.
Third edition of the Training and Employment Forum
The Biospain Organisational Committee has received the support of FEBiotec for this third edition of the Training and Employment Forum next Friday 30th, which will showcase training and job opportunities in companies using a system of scheduled interviews. There will also be a programme on career opportunities, high-demand profiles, and key factors for job searches. A total of 18 companies and training centres as well as 314 participants have registered for the event.
The previous edition in numbers
Biospain 2014, the previous edition, took place in Santiago de Compostela. Of the 855 private and public entities at the fair, which saw an increase of 12.2% compared to the previous edition, 289 came from outside Spain, representing 37 countries, 34% of the total. This compared to 28% at the previous edition. The figure meant that internationalisation had increased by 37.6% since 2012. The biggest number of companies came from Spain (66%), followed by the United Kingdom (6.21%), France (3.51%), Portugal (3.40%), the United States (2.93%), Colombia (2.34%), Mexico (2.34%) and Switzerland (1.87%).
At the 7th edition of Biospain 200 exhibitors and 50 investors were present - 80% of them international - including venture capital funds, big pharma investment funds, business angels and others. All participated in the Investment Forum where the business plans of 40 companies from a range of countries were studied. The partnering event, which was organised in collaboration with the Plataforma de Mercados Biotecnologicos, hosted 3,327 business meetings - an increase of 20% compared to the previous edition - with a total of 2,000 participants (8% more).
During Biospain 2014, there were 50 parallel and scientific conferences, as well as 37 company presentations. In the partnering, 720 products available for licensing were presented. The Biospain Organisational Committee conducted a satisfaction survey among those attending the event. According to the results, 92% of respondents felt that Biospain met or exceeded their expectations. 82% identified real business opportunities and, in terms of the overall assessment of the event, 54% stated that it was good, 19% stated that it was really good, and 24% found it average, meaning that 97% of participants felt satisfied with the event.
The Official Sponsors of Biospain 2016 are Bioibérica, Merck, PharmaMar and Celgene.
Head of Communication for ASEBIO and Biospain 2016
For further information:
Press Office – Berbés Asociados - Tel.: 91 563 23 00
María González – 677 456 806 / Mar de las Heras - 678 54 41 49 / Irene Fernández - 661678283
Biospain 2016 social media accounts:
Inversores de 11 países analizan 30 proyectos de biotecnología españolaRead more
El top ten de fondos de inversión asistentes a Biospain 2016 gestionan activos valorados en más de 5.000 millones de eurosRead more
Los pacientes piden en Biospain 2016 una participación activa en las políticas de salud y en el sistema sanitarioRead more
El descubrimiento del ‘GPS humano’ abre una nueva era en la ingeniería genéticaRead more
La biotecnología agrícola, clave para afrontar el problema de la superpoblación y el cambio climáticoRead more
Biospain 2016 ya cuenta con una APP gratuita para seguir el eventoRead more
US expects to increase its presence in Biospain 2016Read more
Bilbao will host BioSpain 2016Read more
BioSpain 2016 will be the hub of Biotechnology in AutummRead more
Bilbao acogerá BioSpain 2016Read more
EE.UU. prevé incrementar su presencia en Biospain 2016Read more
BioSpain 2016 selecciona a cuatro sociedades científicasRead more
El 82% de los asistentes a Biospain identificaron oportunidades reales de negocioRead more
82% of participants at Biospain identified real business opportunitiesRead more
La inmunoterapia se postula como uno de los pilares terapéuticos del cáncerRead more
La bioeconomía se consolida como una herramienta clave para afrontar los retos futuros del planetaRead more
BioSpain 2014 increases its internationalisation by 43% compared to the previous editionRead more
Participantes en Biospain de 16 países llegarán a la feria por el camino #XacobioRead more
BioSpain 2014 amplía su Foro de Inversión con más perfiles de inversores y más empresas participantesRead more
BioSpain 2014 expands its Investment Forum through wider range of investor profiles and more participating companiesRead more
BioSpain 2014 refuerza su presencia internacional e incorpora el modelo de “Innovación en abierto”Read more
BioSpain 2014 strengthens its international presence and includes ‘Open Innovation’ modelRead more